TY - JOUR
T1 - Minimal clinically important differences in Toronto Extremity Salvage Score for patients with lower extremity sarcoma
AU - Ogura, Koichi
AU - Uehara, Kosuke
AU - Akiyama, Toru
AU - Shinoda, Yusuke
AU - Iwata, Shintaro
AU - Tsukushi, Satoshi
AU - Kobayashi, Eisuke
AU - Hirose, Takeshi
AU - Yonemoto, Tsukasa
AU - Endo, Makoto
AU - Tanzawa, Yoshikazu
AU - Nakatani, Fumihiko
AU - Kawano, Hirotaka
AU - Tanaka, Sakae
AU - Kawai, Akira
N1 - Funding Information:
This study was funded by MEXT KAKENHI Grant Number JP22390296 , and by the National Cancer Center Research and Development Fund ( 23-A-10 and 28-A-16 ). The institution of one or more of the authors (SI, KO, AK) has received, during the study period, funding from the National Cancer Center Research and Development Fund (Grant 26-A-4 ).
Publisher Copyright:
© 2019
PY - 2020/3
Y1 - 2020/3
N2 - Background: The Toronto Extremity Salvage Score (TESS) is the most widely used patient-reported outcome measure for orthopaedic oncology patients. However, minimal clinically important differences (MCIDs) in the TESS have not been analyzed. The aim of this study was to define the MCIDs of TESS in patients with lower extremity sarcoma. Methods: A total of 85 patients were investigated to calculate the MCIDs for TESS. Three different methods were used: 1) distribution-based methods based on one-half of the standard deviation and standard error of measurement (SEM) at the baseline, 2) anchor-based and receiver operating characteristic (ROC) analysis, and 3) anchor-based using Akaike's Information Criterion (AIC) analysis. Results: The MCIDs at 6 months were 4.9–7.8 by distribution-based methods and 4.3–4.4 by anchor-based methods. The MCIDs at 12 months were 4.0–6.9 by distribution-based methods and 10.6–11.6 by anchor-based methods. Conclusions: We calculated MCID values for the TESS based on distribution- and anchor-based approaches. Our results seem reasonable since MCIDs calculated by the different approaches had similar values. This knowledge will enable clinicians to identify meaningful functional improvements in sarcoma patients.
AB - Background: The Toronto Extremity Salvage Score (TESS) is the most widely used patient-reported outcome measure for orthopaedic oncology patients. However, minimal clinically important differences (MCIDs) in the TESS have not been analyzed. The aim of this study was to define the MCIDs of TESS in patients with lower extremity sarcoma. Methods: A total of 85 patients were investigated to calculate the MCIDs for TESS. Three different methods were used: 1) distribution-based methods based on one-half of the standard deviation and standard error of measurement (SEM) at the baseline, 2) anchor-based and receiver operating characteristic (ROC) analysis, and 3) anchor-based using Akaike's Information Criterion (AIC) analysis. Results: The MCIDs at 6 months were 4.9–7.8 by distribution-based methods and 4.3–4.4 by anchor-based methods. The MCIDs at 12 months were 4.0–6.9 by distribution-based methods and 10.6–11.6 by anchor-based methods. Conclusions: We calculated MCID values for the TESS based on distribution- and anchor-based approaches. Our results seem reasonable since MCIDs calculated by the different approaches had similar values. This knowledge will enable clinicians to identify meaningful functional improvements in sarcoma patients.
UR - http://www.scopus.com/inward/record.url?scp=85064264266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064264266&partnerID=8YFLogxK
U2 - 10.1016/j.jos.2019.03.022
DO - 10.1016/j.jos.2019.03.022
M3 - Article
C2 - 31000377
AN - SCOPUS:85064264266
SN - 0949-2658
VL - 25
SP - 315
EP - 318
JO - Journal of Orthopaedic Science
JF - Journal of Orthopaedic Science
IS - 2
ER -